Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2025 Earnings Call Transcript November 6, 2025Esperion Therapeutics, Inc. misses on earnings expectations.
Esperion Therapeutics Inc. (ESPR)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Seas Capital Sina Toussi | 9,749,724 | $25,836,769 | -3% | 0.41% |
| 2. | 10,861,000 | $10,773,135 | 0.06% | ||
| 3. | 8,396,000 | $8,343,525 | +251% | 0.21% | |
| 4. | AIGH Investment Partners Orin Hirschman | 3,000,000 | $7,950,000 | 2.24% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,521,439 | $6,681,814 | -53% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.57 | 23,091 | $36,285.20 | 36,500 | 2023-05-11 | Filing | |
| $1.49 | 8,409 | $12,545.39 | 13,409 | 2023-05-10 | Filing | |
| $1.50 | 8,111 | $12,125.95 | 8,111 | 2023-05-10 | Filing | |
| $1.26 | 20,000 | $25,192.00 | 312,816 | 2023-05-09 | Filing | |
| $7.46 | 1,000 | $7,460.00 | 54,024 | 2022-08-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.80 | 6,267 | $17,572.67 | 393,670 | 2025-09-17 | Filing | |
| $2.79 | 28,427 | $79,254.48 | 1,518,831 | 2025-09-17 | Filing | |
| $2.81 | 7,046 | $19,785.17 | 474,862 | 2025-09-17 | Filing | |
| $1.13 | 1,304 | $1,469.61 | 399,937 | 2025-07-17 | Filing | |
| $1.12 | 11 | $12.27 | 474,462 | 2025-07-17 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 14,833,791 | $39,309,546 | 0% | |
| 2. | 12,092,449 | $32,044,990 | 0% | |
| 3. | 7,061,857 | $18,713,921 | 0.1% | |
| 4. | 6,676,519 | $17,692,775 | 2.98% | |
| 5. | 4,751,396 | $12,593,578 | 0% |
News See All
11 Best Rising Penny Stocks to Buy According to Hedge Funds
On August 22, Tom Lee, Fundstrat's head of research and chief investment officer, appeared on CNBC Television to discuss his reaction to Fed Chair Powell's speech at Jackson Hole, market expectations, ...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2025 Earnings Call Transcript
Operator: Hello, ladies and gentlemen, and thank you for standing by, and welcome to Esperion's Second Quarter 2025 financial results.
Esperion Therapeutics (ESPR) Gets Boost from Acquisition Rumors
Esperion Therapeutics extended its winning streak to a fifth consecutive day on Monday, adding 5.3 percent to close at $1.59 apiece as investors gobbled up shares ahead of its earnings release amid reports...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome. At this time, all participants are in a listen-only mode.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by and welcome. [Operator Instructions] Please be advised that today's conference call may be recorded.
12 Best Small Cap Pharma Stocks to Buy Now
Emily Field, Head of European Pharma Research at Barclays, spoke on CNBC on February 20 about the performance of obesity medications, the effects of US tariffs, and the dynamics of the pharmaceutical ...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by, and welcome. [Operator Instructions] Please be advised that today’s conference call may be recorded.
7 Best NASDAQ Stocks Under $5
A Yahoo Finance report on September 28 reveals that consumers are beginning to feel the effects of a cooling labor market, according to the latest Consumer Confidence Index, which shows a narrowing gap...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript August 12, 2024Esperion Therapeutics, Inc. misses on earnings expectations.
Hedge Fund Resource Center Billionaire Hedge Funds
